Awardee OrganizationRHO FEDERAL SYSTEMS DIVISION, INC.
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT—LEADERSHIP GROUP
The leadership group (LG) will provide strategic and operational direction to the Center. The LG consists
of a director, a senior project manager, the disease-specific group leaders, the centralized group leaders, an
operations team, and various other Center committees. DAIT staff representing each of the three disease
areas, bioinformatics, regulatory, and statistics (as needed) will also be considered part of the larger, external
leadership group.
The proposed LG steering committee provides consistency and clear communication across multiple
studies and functional groups. The LG structure is designed to meet the following primary objectives:
• Centralize and facilitate open lines of communication between Center group leaders and DAIT
• Standardize processes and procedures across the entire program
• Address high-level issues regarding study design, implementation, and analysis
• Keep the Center current with industry and NIH standards
• Provide administrative support to the Center
• Allocate resources across the Center
• Manage the financial aspects of the Center
Members of the LG will build on our past success with coordinating DAIT studies to develop effective
collaboration and communication channels for the Center. These same channels will be used for decision-
making and issue resolution. We have found through our work with large multi-protocol NIH coordinating
centers that effective communication requires a combination of approaches, including scheduled and ad hoc
meetings and teleconferences, use of a collaboration portal to share documents and status information, and
other tools and processes we have developed over time.
Ongoing monitoring and tracking of LG functions and progress is essential to maintaining timely, high
quality work across the Center. Activities must be monitored at the group level and across the Center. The LG
director and senior project manager assume responsibility for monitoring work across the Center.
With the goal of providing all stakeholders with the information needed to evaluate progress and identify
issues and monitor resources, Rho utilizes a number of standard processes, tools, and activities that can be
tailored to the needs of individual projects. As new needs arise, Rho refines these items to continuously
improve our tracking and monitoring methods.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAllergic DiseaseAreaBioinformaticsBudgetsClinicalClinical ResearchCollaborationsCommunicable DiseasesCommunicationDataDecision MakingDiseaseFundingGoalsGroup StructureImmune System DiseasesIndividualIndustryInformation SystemsLeadershipMethodsMissionMonitorNational Institute of Allergy and Infectious DiseaseOccupational activity of managing financesOnline SystemsPerformanceProceduresProcessProtocols documentationResearch DesignResolutionResourcesScheduleStandardizationSystemTeleconferencesTimeU-Series Cooperative AgreementsUnited States National Institutes of HealthWorkcostdesignfunctional groupimprovedmeetingsmemberoperationpreventprogramsrhostatisticssuccesstoolweb site
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
362726007
UEI
XCPKWEM58CV5
Project Start Date
31-August-2021
Project End Date
31-July-2022
Budget Start Date
01-May-2021
Budget End Date
30-April-2022
Project Funding Information for 2021
Total Funding
$3,499,987
Direct Costs
$2,098,691
Indirect Costs
$1,401,296
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$3,499,987
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3UM2AI117870-07S3 8716
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UM2AI117870-07S3 8716
Patents
No Patents information available for 3UM2AI117870-07S3 8716
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UM2AI117870-07S3 8716
Clinical Studies
No Clinical Studies information available for 3UM2AI117870-07S3 8716
News and More
Related News Releases
No news release information available for 3UM2AI117870-07S3 8716
History
No Historical information available for 3UM2AI117870-07S3 8716
Similar Projects
No Similar Projects information available for 3UM2AI117870-07S3 8716